参考文献/References:
[1] McKhann GM,Knopman DS,Chertkow H,et al.The diagnosis of dementia due to Alzheimer’s disease:recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease[J].Alzheimers Dement,2011,7(3):263-269.
[2] Colletier JP,Laganowsky A,Landau M,et al.Molecular basis for amyloid-beta polymorphism[J].Proc Natl Acad Sci USA,2011,108(41):16938-16943.
[3] Jeong JS,Ansaloni A,Mezzenga R,et al.Novel mechanistic insight into the molecular basis of amyloid polymorphism and secondary nucleation during amyloid formation[J].J Mol Biol,2013,425(10):1765-1781.
[4] Kawahara M.Neurotoxicity of β-amyloid protein:oligomerization,channel formation,and calcium dyshomeostasis[J].Curr Pharm Des,2010,16(25):2779-2789.
[5] Hatashita S,Yamasaki H.Clinically different stages of Alzheimer’s disease associated by amyloid deposition with[11C]-PIB PET imaging[J].J Alzheimers Dis,2010,21(3):995-1003.
[6] Vandenberghe R,Van Laere K,Ivanoiu A,et al.18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment:a phase 2 trial[J].Ann Neurol,2010,68(3):319-329.
[7] Hsiao IT,Huang CC,Hsieh CJ,et al.Correlation of early-phase 18F-florbetapir(AV-45/Amyvid) PET images to FDG images:preliminary studies[J].Eur J Nucl Med Mol Imaging,2012,39(4):613-620.
[8] Becker GA,Ichise M,Barthel H,et al.PET quantification of 18F-florbetaben binding to β-amyloid deposits in human brains[J].J Nucl Med,2013,54(5):723-731.
[9] Tauber C,Beaufils E,Hommet C,et al.Brain[18F]FDDNP binding and glucose metabolism in advanced elderly healthy subjects and Alzheimer’s disease patients[J].J Alzheimers Dis,2013,36(2):311-320.
[10] Okamura N,Furumoto S,Harada R,et al.Novel 18F-Labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease[J].J Nucl Med,2013,54(8):1420-1427.
[11] Mathis CA,Bacskai BJ,Kajdasz ST,et al.A lipophilic thioflavin-T derivative for positron emission tomography(PET) imaging of amyloid in brain[J].Bioorg Med Chem Lett,2002,12(3):295-298.
[12] Kemppainen NM,Scheinin NM,Koivunen J,et al.Five-year follow-up of 11C-PIB uptake in Alzheimer’s disease and MCI[J].Eur J Nucl Med Mol Imaging,2014,41(2):283-289.
[13] Clark CM,Schneider JA,Bedell BJ,et al.Use of florbetapir-PET for imaging beta-amyloid pathology[J].JAMA,2011,305(3):275-283.
[14] Rinne JO,Wong DF,Wolk DA,et al.[18F]Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid β detection in living subjects with normal pressure hydrocephalus:pooled analysis of four studies[J].Acta Neuropathol,2012,124(6):833-845.
[15] Hatashita S,Yamasaki H,Suzuki Y,et al.[18F]Flutemetamol amyloid-beta PET imaging compared with[11C]PIB across the spectrum of Alzheimer’s disease[J].Eur J Nucl Med Mol Imaging,2014,41(2):290-300.
[16] Barthel H,Gertz HJ,Dresel S,et al.Cerebral amyloid-beta PET with florbetaben(18F) in patients with Alzheimer’s disease and healthy controls:a multicentre phase 2 diagnostic study[J].Lancet Neurol,2011,10(5):424-435.
[17] Rominger A,Brendel M,Burgold S,et al.Longitudinal assessment of cerebral β-amyloid deposition in mice overexpressing Swedish mutant β-amyloid precursor protein using 18F-florbetaben PET[J].J Nucl Med,2013,54(7):1127-1134.
[18] Thompson PW,Ye L,Morgenstern JL,et al.Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer’s disease pathologies[J].J Neurochem,2009,109(2):623-630.
[19] Ercoli LM,Siddarth P,Kepe V,et al.Differential FDDNP PET patternsin nondemented middle-aged and older adults[J].Am J Geriatr Psychiatry,2009,17(5):397-406.
[20] Tolboom N,Yaqub M,van der Flier WM,et al.Detection of Alzheimer pathology in vivo using both 11C-PIB and 18F-FDDNP PET[J].J Nucl Med,2009,50(2):191-197.
[21] Tolboom N,van der Flier WM,Boverhoff J,et al.Molecular imaging in the diagnosis of Alzheimer’s disease:visual assessment of[ 11C]PIB and[18F]FDDNP PET images[J].J Neurol Neurosurg Psychiatry,2010,81(8):882-884.
[22] Ossenkoppele R,Tolboom N,Foster-Dingley JC,et al.Longitudinal imaging of Alzheimer pathology using[11C]PIB,[18F]FDDNP and[18F]FDG PET[J].Eur J Nucl Med Mol Imaging,2012,39(6):990-1000.
[23] Fodero-Tavoletti MT,Okamura N,Furumoto S,et al.18F-THK523:a novel in vivo tau imaging ligand for Alzheimer’s disease[J].Brain,2011,134(4):1089-1000.
[24] Chien DT,Bahri S,Szardenings AK,et al.Early clinical PET imaging results with the novel PHF-tau radioligand[F-18]-T807[J].J Alzheimers Dis,2013,34(2):457-468.
[25] Van Camp N,Boisgard R,Kuhnast B,et al.In vivo imaging of neuroinflammation:a comparative study between[18F]PBR111,[11C]CLINME and[11C]PK11195 in an acute rodent model[J].Eur J Nucl Med Mol Imaging,2010,37(5):962-972.
[26] Wang M,Gao M,Miller KD,et al.Synthesis of[11C]PBR06 and[18F]PBR06 as agents for positron emission tomographic (PET)imaging of the translocator protein(TSPO)[J].Steroids,2011,76(12):1331-1340.
[27] Damont A,Boisgard R,Kuhnast B,et al.Synthesis of 6-[18F]fluoro-PBR28,a novel radiotracer for imaging the TSPO 18 kDa with PET[J].Bioorg Med Chem Lett,2011,21(16):4819-4822.
[28] Wilms H,Claasen J,R?hl C,et al.Involvement of benzodiazepine receptors in neuroinflammatory and neurodegenerative diseases:evidence from activated microglial cells in vitro[J].Neurobiol Dis,2003,14(3):417-424.
[29] Pascual B,Prieto E,Arbizu J,et al.Decreased carbon-11-flumazenil binding in early Alzheimer’s disease[J].Brain,2012,135(Pt9):2817-2825.
[30] Wong DF,Waterhouse R,Kuwabara H,et al.18F-FPEB,a PET radiopharmaceutical for quantifying metabotropic glutamate 5 receptors:a first-in-human study of radiochemical safety,biokinetics,and radiation dosimetry[J].J Nucl Med,2013,54(3):388-396.
[31] Constantinescu CC,Garcia A,Mirbolooki MR,et al.Evaluation of[18F] Nifene biodistribution and dosimetry based on whole-body PET imaging of mice[J].Nucl Med Biol,2013,40(2):289-294.
[32] Kuwabara H,Wong DF,Gao Y,et al.PET Imaging of nicotinic acetylcholine receptors in baboons with 18F-AZAN,a radioligand with improved brain kinetics[J].J Nucl Med,2012,53(1):121-129.
[33] Bucerius J,Manka C,Schmaljohann J,et al.Feasibility of[18F]-2-Fluoro-A85380-PET imaging of human vascular nicotinic acetylcholine receptors in vivo[J].JACC Cardiovasc Imaging,2012,5(5):528-536.
相似文献/References:
[1]何燕,苏晋,郑晓霞,等.P-糖蛋白抑制剂在PET显像中的应用研究[J].国际放射医学核医学杂志,2016,40(1):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
He Yan,Su Jin,ZhengXiaoxia,et al.Developing P-glycoprotein inhibitor marked by PET[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
[2]许飞,刘建军,黄钢,等.PET乏氧显像在预测肿瘤乏氧及指导临床治疗中的应用进展[J].国际放射医学核医学杂志,2016,40(1):35.[doi:10.3760/cma.j.issn.1673-4114.2016.01.008]
Xu Fei,Liu Jianjun,Huang Gang,et al.The application of hypoxia imaging with PET in predicting tumor hypoxia and guiding clinical therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):35.[doi:10.3760/cma.j.issn.1673-4114.2016.01.008]
[3]张莹莹,王振光,孔艳.PET/CT显像在肺间质纤维化中的应用进展[J].国际放射医学核医学杂志,2016,40(1):55.[doi:10.3760/cma.j.issn.1673-4114.2016.01.011]
Zhang Yingying,Wang Zhenguang,Kong Yan.Application advancement on PET/CT in pulmonary interstitial fibrosis[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):55.[doi:10.3760/cma.j.issn.1673-4114.2016.01.011]
[4]李海峰,张晓军,李云钢,等.国产模块LOOP环改良法合成11C-蛋氨酸[J].国际放射医学核医学杂志,2016,40(2):106.[doi:10.3760/cma.j.issn.1673-4114.2016.02.004]
Li Haifeng,Zhang Xiaojun,Li Yungang,et al.Synthesis of 11C-methionine on home-made module by the improved LOOP method[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):106.[doi:10.3760/cma.j.issn.1673-4114.2016.02.004]
[5]史文杰,孟召伟,谭建.基于Deauville标准探讨18F-FDG PET/CT在霍奇金淋巴瘤复发诊断中的应用价值[J].国际放射医学核医学杂志,2016,40(2):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
Shi Wenjie,Meng Zhaowei,Tan Jian.Value of 18F-FDG PET/CT on diagnosis of Hodgkin lymphoma recurrence using Deauville criterion[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
[6]李海峰,张晓军,张锦明.多巴胺转运蛋白显像剂11C-β-CFT在帕金森病中的应用研究[J].国际放射医学核医学杂志,2016,40(3):218.[doi:10.3760/cma.j.issn.1673-4114.2016.03.011]
Li Haifeng,Zhang Xiaojun,Zhang Jinming.Review of the use of dopamine transporter imaging agent 11C-β-CFT for diagnosing Parkinson disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):218.[doi:10.3760/cma.j.issn.1673-4114.2016.03.011]
[7]尤阳,轩昂,张杰,等.淋巴瘤患者大脑静息葡萄糖代谢改变[J].国际放射医学核医学杂志,2016,40(4):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
You Yang,Xuan Ang,Zhang Jie,et al.Changes in resting-state brain glucose metabolism in patients with lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
[8]王朋,崔邦平,代文莉,等.18F-FDG PET/CT在前列腺癌中的应用进展[J].国际放射医学核医学杂志,2016,40(4):277.[doi:10.3760/cma.j.issn.1673-4114.2016.04.008]
Wang Peng,Cui Bangping,Dai Wenli,et al.Progress in the application of 18F-FDG PET/CT in prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):277.[doi:10.3760/cma.j.issn.1673-4114.2016.04.008]
[9]李菲,黄俊星,张俊.18F-FDG PET/CT在食管癌中的临床应用[J].国际放射医学核医学杂志,2016,40(4):282.[doi:10.3760/cma.j.issn.1673-4114.2016.04.009]
Li Fei,Huang Junxing,Zhang Jun.The clinical application of 18F-FDG PET/CT in esophageal cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):282.[doi:10.3760/cma.j.issn.1673-4114.2016.04.009]
[10]张巍,杨珂.18f正电子放射性药物生产及使用中医务人员的受照剂量研究[J].国际放射医学核医学杂志,2015,39(5):420.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 016]
zhang wei,yang ke..the research of radiation dose of 18f-fdg to pet/ct related personnel[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):420.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 016]
[11]胡伟,赵军.小胶质细胞在AD炎性机制中的作用及其常见PET显像剂的应用进展[J].国际放射医学核医学杂志,2016,40(1):44.[doi:10.3760/cma.j.issn.1673-4114.2016.01.009]
Hu Wei,Zhao Jun.Microglia’s Alzheimer disease inflammatory mechanisms and progress of its common application in PET imaging agents[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):44.[doi:10.3760/cma.j.issn.1673-4114.2016.01.009]
[12]王新艳,管一晖.阿尔茨海默病的影像学诊断进展[J].国际放射医学核医学杂志,2013,37(1):52.[doi:10.3760/cma.j.issn.1673-4114.2013.01.014]
WANG Xin-yan,GUAN Yi-hui.The advancement in Alzheimer disease of imaging diagnosis[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(5):52.[doi:10.3760/cma.j.issn.1673-4114.2013.01.014]
[13]孔艳艳,管一晖,吴平.PET分子探针在阿尔茨海默病早期诊断中的研究进展[J].国际放射医学核医学杂志,2012,36(5):257.[doi:10.3760/cnla.j.issn.1673-4114.2012.05.001]
KONG Yan-yan,GUAN Yi-hui,WU Ping.Novel PET molecular probes for early diagnosis of Alzheimer’s disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(5):257.[doi:10.3760/cnla.j.issn.1673-4114.2012.05.001]
[14]王颖,蔡莉,李彦生,等.11C-PIB PET在不同时期阿尔茨海默病中的研究进展[J].国际放射医学核医学杂志,2013,37(6):378.[doi:10.3760/cma.j.issn.1673-4114.2013.06.013]
WANG Ying,CAI Li,LI Yan-sheng,et al.Application of 11C-PIB PET in different period of the Alzheimer disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(5):378.[doi:10.3760/cma.j.issn.1673-4114.2013.06.013]
[15]范敏,邓玮玮,朱娅华,等.PET在阿尔茨海默病中的应用和进展[J].国际放射医学核医学杂志,2018,(6):553.[doi:10.3760/cma.j.issn.1673-4114.2018.06.014]
Fan Min,Deng Weiwei,Zhu Yahua,et al.Applications and advances of PET imaging in Alzheimer’s disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(5):553.[doi:10.3760/cma.j.issn.1673-4114.2018.06.014]